Indian generics wave next year set to sink obesity drug price

Leading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, potentially up to 80%. This will make the drug more accessible to obese and diabetes patients. The domestic weight-loss drug market is expected to grow substantially. Semaglutide patent expiry will trigger price erosion and increased adoption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0384zN
via IFTTT